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HTake home messages
 Myeloproliferative neoplasm disorders originate from acquiredmutations inHSCs and establish a proinﬂammatory and ﬁbrogenic
niche environment that disrupts normal hematopoiesis and stromal cell populations.
 Gli1+ and LepR+ stromal cells have been recently described as being ﬁbrosis-driving cells that differentiate into myoﬁbroblasts and
produce extracellular matrix in the bone marrow.
 While advances have been made in developing speciﬁc pathway inhibitors; further studies are investigating the use of
combinational therapies to better treat these complex malignancies.élè
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| 14Introduction This paradigm has important consequences for the developmentMyeloproliferative neoplasm (MPN) is a group of diseases that
are closely associated with bone marrow (BM) ﬁbrosis, which is
the continuous replacement of blood-forming cells with exces-
sive scar tissue. In particular, primary myeloﬁbrosis (PMF) is the
prototypical example of the progressive development of BM
ﬁbrosis and BM failure. Despite our advanced understanding of
mutations occurring in hematopoietic stem cells in MPN, the
speciﬁc mechanisms that cause BM ﬁbrosis in PMF are not
understood, in particular as the cells driving ﬁbrosis have
remained obscure for many years and are far less understood
than in organ ﬁbrosis. Overall, the microenvironment becomes
more inﬂammatory and the presence of cytokines and chemo-
kines promotes ﬁbrosis and the dysregulation of normal
hematopoietic stem cells (HSCs). Importantly, accumulative
data suggest that BM ﬁbrosis in MPN is not simply a disease of
the mutated HSC, but rather a disease of the entire HSC niche.ne F.E. Gleitz and Jessica E. Pritchard have contributed equally to the work.
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2 | Educational Updates in Hematology Book | 2019; 3(S2)of novel targeted therapeutics aimed at targeting both the
malignant hematopoietic clone but also the progressing ﬁbrotic
transformation.
The only intervention thought to be curative in myeloﬁbrosis is
allogeneic hematopoietic stem cell transplantation, but the high
treatment-related morbidity and mortality limit its use to
intermediate- or high-risk patients deemed ﬁt to undergo the
procedure. Hence, the majority of PMF patients are treated with
palliative therapies designed to alleviate symptoms and improve
quality of life. The majority of MF patients carry a JAK2 gain-of-
function mutation, known as JAK2 V617F, which leads to the
constitutive activation of the JAK/STAT pathway.1,2 However,
JAK inhibitors such as ruxolitinib provide only limited reduction
in allelic burden, and instead appear to block inﬂammatory
cytokine activity rather than stem-cell derived clonal proliferation,
which primarily drives the disorder.3 Hence, there is a strong
clinical need for speciﬁc treatments that directly target the cause of
the driver mutation or speciﬁc pathway candidates that drive
ﬁbrosis-causing cells.Current state of the art
Recent genetic fate tracing studies have shown that Gli1+ and
LepR+ stromal cells are progenitors of myoﬁbroblasts in BM
ﬁbrosis,
∗4,∗5 which are generally accepted to be the ﬁbrosis-
causing cells across multiple organ systems. In murine models of
BM ﬁbrosis/PMF, Gli1+ cells are recruited from the endosteal
niche, become activated and differentiate into myoﬁbroblasts
(Fig. 1). Importantly, in murine models of thrombopoietin-
induced ﬁbrosis, genetic ablation of these Gli1+ stromal cells
completely ameliorated BM ﬁbrosis and prevented BM failure.
∗5
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Figure 1. Reprogrammedbonemarrownichewith speciﬁc focus on recently identiﬁed stromal cell populations relevant toMPN. MPNclone
gives rise to mutant, dysplastic megakaryocytes that secrete CXCL4 and other ﬁbrogenic cytokines. This release of proinﬂammatory molecules
alters the sensitive bone marrow microenvironment, which affects stromal populations such as Nestin+ cells that lose their capacity to support
hematopoiesis (CXCL12, SCF). Through these changes, other stromal populations such as Gli+ and LepR+ acquire an abnormal phenotype, leading
to activation, increased proliferation, and migration into the marrow space where they differentiate into myoﬁbroblasts and deposit collagen and
reticulin ﬁbers. Canonical Hedgehog signaling can be inhibited by various smoothened (SMO) inhibitors, although recent data suggest that Gli can be
directly inhibited by GANT1 or through inhibiting the noncanonical pathway. Other pathways, such as PDGF signaling, are also involved in ﬁbrotic
transformation, and can be targeted by speciﬁc inhibitors such as Imatinib. It was shown that PDGFmay activate Gli through noncanonical signaling.
MPN = myeloproliferative neoplasm.
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Gleitz et al. Fibrosis Driving Myofibroblast Precursors in MPN and New Therapeutic PathwaysRNA-sequencing experiments in mouse models of PMF
indicated that megakaryocyte-associated genes were signiﬁcant-
ly up-regulated, and led to the identiﬁcation of CXCL4 as a
potential activator of Gli1+ cells. Furthermore, it was shown
that the expression of Hedgehog (Hh) target genes is
signiﬁcantly increased in patient granulocytes, and that Gli1
expression is signiﬁcantly increased in MPN patients.
∗6
However, the exact role and contribution of the Hh pathway
in MF are still not completely understood. GANT1, a small
molecule Gli protein inhibitor, is able to inhibit Gli1+ cell
expansion and myoﬁbroblast differentiation, and attenuates
ﬁbrosis severity, in both murine and human Gli1+ MSCs.
∗5
Therefore, there is strong evidence for targeted therapies of Gli
proteins in BM ﬁbrosis, either as monotherapy or combined
therapy with other agents. In particular, the combination of
JAK2 inhibitors with inhibitors of the Hh pathway might
provide a novel therapeutic avenue to target clonal myelopro-
liferation and ﬁbrosis. However, thus far, only smoothened
(SMO) inhibitors, which inhibit canonical (Hh ligand depen-
dent) signaling, have been tested with varying success.7 This is
likely because Gli protein in Gli1+ cells can also be activated via
noncanonical Hh signaling (ie, by phosphoinositide-3-kinase-
AKT, TGFb, PDGF signaling), explaining the variable response
of SMO inhibition in MF patients.
Another population of stromal cells shown to directly
contribute to BM ﬁbrosis through their differentiation into
myoﬁbroblasts are LepR+ cells.
∗4 During normal BM function,
LepR+ stromal cells produce CXCL12, an important support
factor that is crucial for HSC survival and regulation.8 In BM
ﬁbrosis, these cells have been shown to expand signiﬁcantly
and differentiate upon activation of the PDGFRa pathway, a
pathway that is well known to be important in organ
ﬁbrosis (Fig. 1). Administration of Imatinib, which blocks
the activity of several tyrosine kinases, including PDGFRa,
or conditional deletion of platelet-derived growth factor
receptor a (Pdgfra) from LepR+ stromal cells, ameliorated BM
ﬁbrosis, indicating that the PDGFRa pathway plays an
important role in ﬁbrosis not only in solid organs but also
in BM ﬁbrosis.
∗4
While not directly involved in the deposition of ﬁbrosis,
Nestin+ stromal cells are also affected by the proinﬂammatory
environment during PMF.
∗9 In the presence of an MPN
hematopoietic clone, Nestin+ stromal cells undergo apoptosis
and alter their activity, shown by a down-regulation of
hematopoiesis support cytokines such as CXCL12 and SCF,
thereby altering the BM niche (Fig. 1). Nestin+ cells are
innervated by sympathetic nerve ﬁbers and regulate normal
HSCs. In MPN, IL-1b produced from mutant HSCs results in
neural damage that depletes Schwann cells leading to neuropa-
thy and accelerated MPN progression.
∗9 Overall, these studies
highlight the idea of a self-reinforcing malignant niche, which
favors disease progression instead of normal HSCs by means of
aberrant cytokine production and dysregulated differentiation
programs.
Future perspectives
Other strategies aiming at preventing or slowing down the
development of the proﬁbrotic niche could prove useful in
restoring normal hematopoiesis and disrupting the malignant
self-reinforcing niche. Several immunomodulatory drugs such as
thalidomide and lenalidomide, proteasome inhibitors (bortezo-
mib), and VEGF-targeting agents (sunitinib and bevacizumab)
have been tested to modify the microenvironment in patient
subsets, with mixed results hampered by tolerability issues.10
Inﬂammatory and ﬁbrogenic cytokines that are known to| 144 | Educational Updates in Hematology Book | 2019; 3(S2)partially drive ﬁbrotic transformation and BM niche remodeling
in mice, such as PDGF and TGF-b, can also likely be targeted
using suppressing, neutralizing, or antagonizing antibodies
currently available in the clinic, or in combination with
ruxolitinib, an already active area of research in PMF.11 The
antiﬁbrotic compound Pirfenidone (FDA approved for idio-
pathic pulmonary ﬁbrosis), which inhibits TGF-b and p38
signaling, was trialed in 2001 but led to no improvement in
anemia, spleen weight, or BM ﬁbrosis. Subsequently, other
strategies such as the biologic simtuzumab may focus on
inhibiting extracellular matrix deposition, by interfering with
the cross-linking of collagen and elastin ﬁbers, although this
showed limited effect on BM ﬁbrosis severity.12 Hypomethylat-
ing agents such as decitabine were shown to increase overall
survival in high-risk PMF patients,13 although additional
treatment modalities combining decitabine and other active
agents are required for improved income. With our understand-
ing of BM ﬁbrosis and its dysregulated pathways, it seems that
targeting inﬂammatory or ﬁbrogenic cytokines alone may not be
enough, and instead requires the targeting of multiple pathways
to effectively block the interaction between malignant hemato-
poietic cells, inﬂammatory cytokines, dysplastic megakaryo-
cytes, and ﬁbrosis-driving cells.Conclusion
The recent identiﬁcation of Gli1+ and LepR+ cells as myeloﬁbrotic
precursors is the ﬁrst important step in developing antiﬁbrotic
therapies for PMF, together with the identiﬁcation of deregulated
pathways that provide attractive therapeutic avenues.References
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